Company Profiles

driven by the PitchBook Platform

Lycera

Lycera
2006 FOUNDED
PRIVATE STATUS
51-200 EMPLOYEES
Series B LATEST DEAL TYPE
$29.9M LATEST DEAL AMOUNT
$115M TOTAL AMOUNT RAISED
Description

Developer of molecule therapies and drugs for the treatment of autoimmune diseases and cancer. The company engages in research and development of drugs for the treatment of diseases such as psoriasis, rheumatoid arthritis, lupus erythematosis, inflammatory bowel disease, cancer and other autoimmune disease.

Website:
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
2800 Plymouth Road
NCRC, Building 26
Ann Arbor, MI 48109
United States

+1 (734) 233-3060
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Lycera’s full profile, request a free trial.

Lycera Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC (Series B) 19-Jun-2015 $29.9M $115M 00000 Completed Generating Revenue
7. Convertible Debt 04-Apr-2014 000 000.00 Completed Generating Revenue
6. Debt - General 21-Oct-2013 000 000.00 Completed Generating Revenue
5. Early Stage VC 28-Jun-2012 000.00 000.00 Completed Generating Revenue
4. Early Stage VC (Series A) 05-May-2009 0000 000.00 000.00 Completed Startup
3. Secured Debt 07-Nov-2008 00000 00.000 Completed Startup
2. Early Stage VC 01-Jul-2008 $750k Completed Startup
1. Convertible Debt 03-Nov-2006 $750k $750k Completed Startup
To view this company’s complete deal history including valuation and funding request access »

Lycera Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series C 0 00.000000
Series B1 00,000,000 00.000000 00 00.00 00.00 00 00.00
Series B 50,728,020 $0.000100 8% $0.63 $0.63 1x $0.63 19.15%
Series A 126,772,402 $0.000100 8% $0.32 $0.32 1x $0.32 51.17%
To view this company’s complete Cap Table request access »

Lycera Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
ARCH Venture Partners Venture Capital Minority 000 0000 000000 0
Clarus Ventures Venture Capital Minority 000 0000 000000 0
EDF Ventures Venture Capital Minority 000 0000 000000 0
InterWest Healthcare Partners Venture Capital Minority 000 0000 000000 0
Michigan Investment in New Technology Startups Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »

Lycera Executive Team (12)

Name Title Board
Seat
Contact
Info
Alex Howarth Chief Financial Officer
Bruce Goldsmith Ph.D Chief Operating Officer and Chief Business Officer
Laura Carter Senior Vice President, Biology
Peter Toogood Ph.D Senior Vice President of Chemistry and Chemical Biology
JoAnn Scatina Senior Vice President of Preclinical Development
You’re viewing 5 of 12 executives. Get the full list »

Lycera Board Members (12)

Name Representing Role Since Contact
Info
Finny Kuruvilla Ph.D Clarus Ventures Board Observer 000 0000
Jeffrey Leiden Ph.D Clarus Ventures Board Member 000 0000
Kristina Burow ARCH Venture Partners Board Member 000 0000
Mary Campbell EDF Ventures Board Observer 000 0000
Michael Hayden Self Board Member 000 0000

1 Former Board Members

You’re viewing 5 of 12 board members. Get the full list »